Are you ready to join a team committed to making a meaningful impact on cancer treatment through the discovery and development of precision medicines? At Kura Oncology, you have an opportunity to be a part of something bigger, with a lasting impact that you can be proud of.
At Kura Oncology, we are working to change the paradigm and improve the science of cancer treatment. As an organization, we strive to cultivate a diverse and talented professional culture driven to develop precision medicine therapeutics.
As we continue to build a leading biotech organization with a strong culture, a patient-focused mindset and a team focused on relentless execution, we are looking for innovative, passionate professionals to join us and make our vision a reality.
To succeed at Kura, you will need to have a demonstrated ability for excellence in drug discovery and development and a roll-up your sleeves attitude. The ideal candidate will possess a values-driven work style where integrity and grit drive all behaviors, decisions, and actions.
ESSENTIAL JOB FUNCTIONS:
High-exposure, key Commercial leadership role with responsibility for pricing and contracting across critical GPO, government and commercial channels, and key customer partnerships. The incumbent will be responsible for directing compliant internal price-setting and monitoring processes (e.g., creating and leading cross-functional Pricing Committee) including gross-to-net management, forecasting scenarios, as well as all external Federal and State price reporting requirements.
Finally, this will be a strategic opportunity to work closely with key stakeholders to identify and execute agreements that reflect the full value of Kura’s future products. This individual will work closely with Market Access, Marketing, Trade and Distribution, Field teams, Finance, and Legal to ensure alignment to corporate goals and brand targets.
- Deliver launch pricing and contracting strategy for Ziftomenib across prioritized channels and customer segments working closely with the cross-functional leadership and executive teams at Kura and our commercialization partner Kyowa Kirin.
- Critical channels and customers include: Oncology GPOs, Oncology Centers of Excellence, commercial and government entities.
- Oversee and be responsible for all price reporting to Federal/State government agencies on a monthly/quarterly/annual basis (e.g., Medicaid BP, AMP, ASP, and PHS, etc.)
- Monitor the activity of contracts, including varied price concessions such as chargebacks, rebates and fees to evaluate the impact on AMP, Best Price, ASP, NFAMP, and PHS calculations in accordance with the policies of CMS, the VA, and the PHS
- Build relevant SOPs and internal processes working closely with Finance/Field Access Lead/Distribution/Legal and maintain module for gross-to-net reporting to finance inclusive of administrative duties – regularly monitor pricing compliances/deviation
- Perform timely pricing analysis and guidance to sales, marketing and corporate accounts organizations. Develop strategies for improvement/managing of gross-to-nets (GtN); evaluate against brand strategy and report results to business stakeholders
- Prepare contract offers based on data analysis, identifying risks, and developing strategic recommendations for presentation and approval to upper management
- Be able to support the US team on pricing aspects for pipeline assets
- Partner with ex-US commercialization partner to build a global pricing framework that ensures appropriate input from the US pricing committee
JOB SPECIFICATIONS:
- Bachelor’s degree in related field or science, MBA or advanced degrees preferred
- 7-10 years of pharma/biotech/or related consulting experience with more than 4-5 years in pricing and contracting including strategic understanding of U.S. healthcare dynamics, market access, and reimbursement
- Strong Financial acumen, Strategic Thinker, and highly Analytical
- A team player that can influence the matrix and drive forward results
- Advanced hands-on skills in Excel, modeling (e.g., ASP modeling and Forecast/GtN), and a strong track record of being part of pricing committee and customer negotiations
- Displays strong business acumen and is comfortable working in a fast-moving, ambiguous start-up environment – self-starter and problem-solver
- Ability to influence executive and cross-functional leadership teams
- Strong negotiation skills and experience
The base range for a Director is $214,145 - $244,185 per year. Individual pay may vary based on additional factors, including, and without limitation, job-related skills, experience, work location, and relevant education or training. Kura's compensation package also includes generous benefits, equity, and participation in an annual target bonus.
Kura’s Values that are used for candidate selection and performance assessments:
- We work as one for patients
- We are goal-focused and deliver with excellence
- We are science-driven courageous innovators
- We strive to bring out the best in each other and ourselves
The Kura Package
- Career advancement/ development opportunities
- Competitive comp package
- Bonus
- 401K + Employer contributions
- Generous stock options
- ESPP Plan
- 20 days of PTO to start
- 18 Holidays (Including Summer & Winter Break)
- Generous Benefits Package with a variety of plans available with a substantial employer match
- Paid Paternity/Maternity Leave
- In-Office Catered lunches
- Home Office Setup
- Lifestyle Spending Stipend
- Commuter Stipend (Boston Office)
- Regular employee social activities, including happy hours, monthly birthday celebrations, Kura Koffee Talks, and much more!
Kura Oncology is a clinical-stage biopharmaceutical company discovering and developing personalized therapeutics for the treatment of blood cancers and solid tumors. The company’s diverse pipeline consists of small molecules that target cancer signaling pathways where there is a strong scientific and clinical rationale to improve outcomes by identifying those patients most likely to benefit from treatment. Kura Oncology’s approach to drug development is focused on rapidly translating novel science into life-saving medicines. Our goal is to help patients with cancer lead better, longer lives. Kura Oncology has offices in San Diego, California, and Boston, Massachusetts.
Kura’s pipeline consists of three investigational drug candidates: ziftomenib, tipifarnib and KO-2806. Ziftomenib, a once-daily, oral drug candidate targeting the menin-KMT2A protein-protein interaction, has received Breakthrough Therapy Designation for the treatment of R/R NPM1-mutant acute myeloid leukemia (AML). Kura has completed enrollment in a Phase 2 registration-directed trial of ziftomenib in R/R NPM1-mutant AML (KOMET-001). The Company is also conducting a series of clinical trials to evaluate ziftomenib in combination with current standards of care in newly diagnosed and R/R NPM1-mutant and KMT2A-rearranged AML. Tipifarnib, a potent and selective farnesyl transferase inhibitor (FTI), is currently in a Phase 1/2 trial in combination with alpelisib for patients with PIK3CA-dependent head and neck squamous cell carcinoma (KURRENT-HN). Kura is also evaluating KO-2806, a next-generation FTI, in a Phase 1 dose-escalation trial as a monotherapy and in combination with targeted therapies (FIT-001). For additional information, please visit Kura’s website at www.kuraoncology.com and follow us on X and LinkedIn.
Kura Oncology is committed to creating a diverse environment and is proud to be an equal opportunity employer. All qualified applicants will receive consideration for employment without regard to race, color, religion, gender, gender identity or expression, sexual orientation, national origin, genetics, disability, age, or veteran status.
What We Do
Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. Our small-molecule drug candidates target signaling pathways and other drivers of cancer where there is a strong scientific and clinical rationale to improve outcomes by identifying those patients most likely to benefit from treatment.
Our pipeline includes tipifarnib, a farnesyl transferase inhibitor, currently in a registration-directed clinical trial and KO-539, a menin-MLL inhibitor, currently in a Phase 1/2A clinical trial.
For additional information, please visit our website at www.kuraoncology.com.
